Please assess the completion status of the following clinical trial:

Trial Title: Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of adenocarcinoma of the prostate; stage T1-T3, N0-N1, M0~* Prior definitive therapy for primary prostate cancer consisting of:external beam radiotherapy;brachytherapy with or without pelvic external beam radiation; or radical prostatectomy with or without adjuvant or salvage radiation therapy~* Therapeutic PSA response to primary therapy below 1.0 ng/ml post radiation therapy or below 0.4 ng/ml for radical prostatectomy~* Patients treated with adjuvant or salvage radiation therapy following radical prostatectomy are eligible provided:Post prostatectomy PSA was never \> 6.0 ng/ml, last effective day of androgen deprivation is at least 3 months prior to study entry~* Recurrent PSA level elevation (between 0.4 ng/ml and 6.0 ng/ml) on two determinations at least one week apart.~* No clinical evidence of gross local recurrence or known metastatic disease other than PSA elevation. Transrectal ultrasound and/or biopsy to evaluate local recurrence is not required. All patients will receive a bone scan and CT scan of the abdomen to exclude metastases.~* Estimated life expectancy of at least 6 months.~* ECOG Performance status of 0 or 1.~* Willing and able to give informed consent.~Exclusion Criteria:~* Cryosurgery as definitive therapy of primary tumor.~* Any metastasis.~* No concurrent or prior malignancy is allowed except for the following: adequately treated basal or squamous cell skin cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.~* Current systemic steroid therapy (inhaled or topical steroids acceptable).~* Prior hormonal therapy for treatment of progressive disease.~* Prior chemotherapy, immunotherapy, or therapy with other experimental agents for prostate cancer.~* Any surgery within the prior 4 weeks.~* Bilirubin and SGOT \> 2 x upper limit of normal.~* BUN and serum creatinine \> 2.0 times normal.~* No active congestive heart failure.~* If there is a history of clinically significant obstructive airway disease, a DLCO must exceed 50%.~* Active uncontrolled bacterial, viral or fungal infection until these conditions are corrected or controlled.~* Any underlying medical condition which in the principal investigator's opinion will make the administration of GM-CSF hazardous or obscure the interpretation of adverse events.~* PSA \> 6.0 ng/ml

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).